Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples

BackgroundColorectal cancer (CRC) is a heterogeneous disease with different molecular characteristics associated with many variables such as the sites from which the tumors originate or the presence or absence of chromosomal instability. Identification of such variables, particularly mutational hotspots, often carries a significant diagnostic and/or prognostic value that could ultimately affect the therapeutic outcome.MethodsHigh-throughput mutational analysis of 99 CRC formalin-fixed and paraffin-embedded (FFPE) cases was performed using the Cancer Hotspots Panel (CHP) v2 on the Ion Torrent™ platform. Correlation with survival and other Clinicopathological parameters was performed using Fisher’s exact test and Kaplan–Meier curve analysis.ResultsTargeted sequencing lead to the identification of frequent mutations in TP53 (65 %), APC (36 %), KRAS (35 %), PIK3CA (19 %), PTEN (13 %), EGFR (11 %), SMAD4 (11 %), and FBXW7 (7 %). Other genes harbored mutations at lower frequency. EGFR mutations were relatively frequent and significantly associated with young age of onset (p = 0.028). Additionally, EGFR or PIK3CA mutations were a marker for poor disease-specific survival in our cohort (p = 0.009 and p = 0.032, respectively). Interestingly, KRAS or PIK3CA mutations were significantly associated with poor disease-specific survival in cases with wild-type TP53 (p = 0.001 and p = 0.02, respectively).ConclusionsFrequent EGFR mutations in this cohort as well as the differential prognostic potential of KRAS and PIK3CA in the presence or absence of detectable TP53 mutations may serve as novel prognostic tools for CRC in patients from the Kingdom of Saudi Arabia. Such findings could help in the clinical decision-making regarding therapeutic intervention for individual patients and provide better diagnosis or prognosis in this locality.

[1]  William M. Grady,et al.  Epigenetics and colorectal cancer , 2011, Nature Reviews Gastroenterology &Hepatology.

[2]  D. Sargent,et al.  Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications , 2012, Clinical Cancer Research.

[3]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[4]  A. Rustgi,et al.  A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4) , 2004, The Lancet.

[5]  Yoko Yamamoto,et al.  Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Botti,et al.  Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Maria Vergoulidou More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds , 2015, Biomarker insights.

[8]  D. Busam,et al.  Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer , 2015, British Journal of Cancer.

[9]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[10]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[11]  R. Xu,et al.  Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. , 2014, World journal of gastroenterology.

[12]  Kathleen R. Cho,et al.  Identification of a chromosome 18q gene that is altered in colorectal cancers. , 1990, Science.

[13]  Bert Vogelstein,et al.  APC mutations occur early during colorectal tumorigenesis , 1992, Nature.

[14]  C. Purdie,et al.  17q allele loss is associated with lymph node metastasis in locally aggressive human colorectal cancer , 1995, The Journal of pathology.

[15]  John Quackenbush,et al.  Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample , 2008, PloS one.

[16]  K. Wiman,et al.  Mutant p53 reactivation by small molecules makes its way to the clinic , 2014, FEBS letters.

[17]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[18]  H. Schulten,et al.  Methylation of the Polycomb Group Target Genes Is a Possible Biomarker for Favorable Prognosis in Colorectal Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.